Do you want to read an article? Please log in or register.
Effects of Intravitreal Aflibercept on Galectin-1 and Vascular Endothelial Growth Factor-A Plasma Levels in Patients with Diabetic Retinopathy
Macular DiseasesRetinal Diseases
Related content
Further Publications
Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial
JAMA Ophthalmol
Maturi RK, Glassman AR, Josic K, Antoszyk AN, Blodi BA, Jampol LM, Marcus DM, Martin DF, Melia M, Salehi-Had H, Stockdale CR, Punjabi OS, Sun JK, DRCR Retina Network.
doi: 10.1001/jamaophthalmol.2021.0606
COMMENTED
Macular DiseasesRetinal Diseases
IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA
Retina.
Wirth MA, Wons J, Freiberg FJ, Becker MD, Michels S
doi: 10.1097/IAE.
Glaucoma and Ocular PressureMacular Diseases
A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema
BMC Ophthalmol.
He Y, Ren XJ, Hu BJ, Lam WC, Li XR
doi: 10.1186/s12886-018-0779-1.
Macular Diseases
Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial
JAMA Ophthalmol.
Bressler SB, Odia I, Maguire MG, Dhoot DS, Glassman AR, Jampol LM, Marcus DM, Solomon SD, Sun JK; Diabetic Retinopathy Clinical Research Network
doi: 10.1001/jamaophthalmol.
Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology
Ophthalmology.
VanderVeen DK, Melia M, Yang MB, Hutchinson AK, Wilson LB, Lambert SR
doi: 10.1016/
COMMENTED
Retinal Diseases
Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy
Ophthalmology.
Sun JK, Glassman AR, Beaulieu WT, Stockdale CR, Bressler NM, Flaxel C, Gross JG, Shami M, Jampol LM
doi: 10.1016/
RECOMMENDED
Macular Diseases
COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE
Retina.
Weiss M, Sim DA, Herold T, Schumann RG, Liegl R, Kern C, Kreutzer T, Schiefelbein J, Rottmann M, Priglinger S, KortUEm KU
doi: 10.1097/IAE.
COMMENTED
Retinal Diseases
Multicentre study of 4626 patients assesses the effectiveness, safety and burden of two categories of treatments for central retinal vein occlusion: intravitreal anti-vascular endothelial growth factor injections and intravitreal Ozurdex injections
★ 2
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Br J Ophthalmol
Gale R, Gill C, Pikoula M, Lee AY, Hanson RLW, Denaxas S, Egan C, Tufail A, Taylor P, UK EMR Database Users Group.
doi: 10.1136/bjophthalmol-2020-317306
Retinal Diseases
Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a systematic review and network meta-analysis
Acta Ophthalmol
Fallico M, Maugeri A, Lotery A, Longo A, Bonfiglio V, Russo A, Avitabile T, Pulvirenti A, Furino C, Cennamo G, Barchitta M, Agodi A, Reibaldi M
doi: 10.1111/aos.14681